Bristol-Myers Squibb Company

NYSE:BMY

Drug Manufacturers - General

Healthcare
$59.56 -2.57%

-$1.42 today

Market cap
$121.75B
Beta
0.24
P/E (TTM)
15.1
EPS (TTM)
$3.56
Dividend yield
4.64%
52W Low $42.52High $62.89

Volume 9.54M

Average 11.50M

BMY Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Bristol-Myers Squibb CompanyNYSE: BMY

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q2 FY2026 weighted avg shares (diluted) of 2.05B shares rose 0.5% year over year, in line with the +0.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.2% from the prior quarter. Over 3 fiscal years it compounded at -1.7% a year.

Context

  • Weighted avg shares (diluted) increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +0.5% holds above the trailing-twelve-month pace of +0.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
2.05B+0.2% QoQ
Last fiscal yearDec 2025
2.04B+0.7% YoY
LTMJun 2026
2.04B+0.3% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.5%——
1 year+0.7%——
3-year CAGR-1.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
2.04B USD
Year-over-year change
+0.7%
4-year CAGR
-2.4%

Weighted Avg Shares (Diluted) vs competitors

How BMY compares with its peers on the latest reported figures

  • BMY's LTM Jun 2026 weighted avg shares (diluted) of 2.04B shares is the 4th highest of the 11 companies compared; the peer median is 1.85B shares.
  • Its year-over-year change of +0.3% is the 2nd highest of 11, against a peer median of -0.2%.
  • Over three fiscal years its annual growth of -1.7% compares with a peer median of -0.2%.
BMY Competitors Peer median
Weighted Avg Shares (Diluted) for BMY and competitors
Company Period LTM YoY 3-year CAGR
PFEPfizer Inc.LTM Jun 20265.71B +0.0%-0.3%
MRKMerck & Co., Inc.LTM Jun 20262.48B -1.9%-0.5%
JNJJohnson & JohnsonLTM Sep 20262.44B +0.8%-3.0%
BMYBristol-Myers Squibb CompanyLTM Jun 20262.04B +0.3%-1.7%
GSKGSK plcLTM Jun 20262.04B -0.9%+0.3%
NVSNovartis AGLTM Jun 20261.92B -3.4%-3.8%
ABBVAbbVie Inc.LTM Sep 20261.77B +0.0%-0.1%
AZNAstraZeneca PLCLTM Sep 20261.56B +0.0%+0.0%
GILDGilead Sciences, Inc.LTM Jun 20261.25B -0.5%-0.2%
LLYEli Lilly and CompanyLTM Jun 2026896.6M -0.6%-1.9%
AMGNAmgen Inc.LTM Jun 2026543.25M +0.3%+0.1%
Peer median (excluding BMY) 1.85B-0.2%-0.2%

Competitors are the stored peer set for BMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue46.39B46.16B45.01B48.3B48.2B
Cost of Revenue9.94B10.14B10.69B13.97B13.94B
Gross Profit36.45B36.02B34.31B34.33B34.26B
Gross Margin78.6%78.0%76.2%71.1%71.1%
Research & Development10.2B9.51B9.3B11.16B9.95B
Selling, General & Admin7.69B7.81B7.77B8.41B7.27B
Operating Expenses27.91B26.92B26.12B28.45B20.54B
Depreciation & Amortization10.69B10.28B9.76B9.6B4.01B
EBITDA20.12B19.22B19.37B3.17B15.23B
EBITDA Margin43.4%41.6%43.0%6.6%31.6%
Operating Income8.54B9.1B8.2B5.89B13.72B
Operating Margin18.4%19.7%18.2%12.2%28.5%
Interest Income00000
Interest Expense1.33B1.23B1.17B1.95B1.89B
Other Income / Expenses(439M)(1.39B)245M(14.27B)(4.4B)
Income Before Tax8.1B7.71B8.44B(8.38B)9.33B
Pre-Tax Margin17.5%16.7%18.8%-17.3%19.4%
Income Tax Expense1.08B1.37B400M554M2.27B
Net Income6.99B6.33B8.03B(8.95B)7.05B
Net Margin15.1%13.7%17.8%-18.5%14.6%
EPS (Basic)3.152.973.88(4.41)3.46
EPS (Diluted)3.122.953.86(4.41)3.45
Weighted Avg Shares2.22B2.13B2.07B2.03B2.04B
Weighted Avg Shares (Diluted)2.25B2.15B2.08B2.03B2.04B

Bristol-Myers Squibb Company

NYSE:BMY

Intrinsic Alpha fair value

Locked

Current Price

$59.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.